Shares of agilon health, inc. (NYSE:AGL – Get Free Report) have been given a consensus rating of “Reduce” by the twenty-one brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.28.
Several equities analysts have weighed in on the company. Stifel Nicolaus dropped their price objective on agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a research note on Tuesday, November 12th. Bank of America lowered shares of agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research report on Wednesday, October 2nd. JMP Securities downgraded shares of agilon health from an “outperform” rating to a “market perform” rating in a research report on Monday, November 11th. Macquarie started coverage on shares of agilon health in a research note on Monday, December 16th. They issued a “neutral” rating and a $3.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $3.00 target price on shares of agilon health in a research note on Tuesday, November 19th.
View Our Latest Stock Report on agilon health
agilon health Trading Up 0.5 %
agilon health (NYSE:AGL – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). The company had revenue of $1.45 billion during the quarter, compared to analysts’ expectations of $1.47 billion. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. During the same period last year, the company earned ($0.06) earnings per share. As a group, research analysts predict that agilon health will post -0.52 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director John William Wulf purchased 45,000 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was purchased at an average cost of $2.18 per share, with a total value of $98,100.00. Following the completion of the acquisition, the director now directly owns 206,133 shares of the company’s stock, valued at approximately $449,369.94. The trade was a 27.93 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen Mcloughlin purchased 25,000 shares of agilon health stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $2.20 per share, with a total value of $55,000.00. Following the completion of the transaction, the director now owns 73,166 shares of the company’s stock, valued at $160,965.20. This represents a 51.90 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 90,000 shares of company stock worth $198,100 over the last quarter. 3.20% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On agilon health
Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock worth $5,563,000 after acquiring an additional 1,083,492 shares during the period. Virtu Financial LLC bought a new position in shares of agilon health in the third quarter worth $120,000. Geode Capital Management LLC raised its position in shares of agilon health by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company’s stock worth $27,097,000 after buying an additional 84,889 shares in the last quarter. Barclays PLC boosted its stake in agilon health by 21.2% during the third quarter. Barclays PLC now owns 1,228,952 shares of the company’s stock valued at $4,830,000 after buying an additional 214,830 shares during the period. Finally, XTX Topco Ltd grew its position in agilon health by 271.1% during the third quarter. XTX Topco Ltd now owns 119,747 shares of the company’s stock worth $471,000 after buying an additional 87,481 shares in the last quarter.
About agilon health
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Recommended Stories
- Five stocks we like better than agilon health
- The Significance of Brokerage Rankings in Stock Selection
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Stock Analyst Ratings and Canadian Analyst Ratings
- These 3 Quirky ETFs May Be Strong Plays in 2025
- Differences Between Momentum Investing and Long Term Investing
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.